GRAIL Inc. (GRAL) vs Ionis Pharmaceuticals, Inc. (IONS)
A side-by-side comparison of GRAIL Inc. and Ionis Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GRAL
GRAIL Inc.
$137.28HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
IONS
Ionis Pharmaceuticals, Inc.
$44.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GRAL vs IONS
growth of $100 · dividends reinvested · last 2yGRAL +1028.0% (+235.9%/yr)IONS +8.6% (+4.2%/yr)GRAL compounded faster over this window
Log scale — wide-divergence pair
GRAL IONS
GRAL vs IONS: by the numbers
- •IONS is the larger company ($7.31B vs $5.89B market cap).
- •Both run net losses; IONS's is the smaller (-64.64% vs -236.95% net margin).
Metrics side by side
Valuation
| Metric | GRAL | IONS |
|---|---|---|
| P/S ratio | 35.65 | 8.37 |
| P/B ratio | 2.32 | 16.63 |
| EV / EBITDA | N/A | 2.21 |
Profitability
| Metric | GRAL | IONS |
|---|---|---|
| Gross margin | -42.52% | 98.16% |
| Operating margin | -362.95% | -40.47% |
| Net margin | -236.95% | -64.64% |
| ROE | -15.40% | -128.44% |
| ROIC | -20.26% | -20.37% |
Growth (annualized)
| Metric | GRAL | IONS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 4.91% |
| Total return CAGR (5Y) | N/A | 5.82% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.